NASDAQ
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $1.07B and net income of $391.00M for FY 2025. The gross profit margin is 91.7% with a net profit margin of 36.5%.
Financial data for ACAD
11.87% YoY
72.66% YoY
69.34% YoY
Annual Income Statement for ACAD
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1B | $958M | $726M | $517M | $484M |
| Cost of Revenue | $89M | $82M | $46M | $10M | $19M |
| Gross Profit | $983M | $876M | $681M | $507M | $465M |
| Operating Expenses | $878M | $645M | $754M | $731M | $635M |
| Operating Income | $105M | $231M | -$73M | -$224M | -$170M |
| Net Income | $391M | $226M | -$61M | -$216M | -$168M |
| EPS | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 |
| EBITDA | $139M | $100M | -$68M | -$222M | -$167M |
No price data available for this timeframe.